The summit will address priority patient inputs for comparative effectiveness research and health technology assessments.
Alexandria, VA — April 27, 2021 — The Innovation and Value Initiative (IVI), an independent nonprofit research organization dedicated to advancing patient-centric value assessment, today announced it will convene the second annual Methods Summit, a multi-stakeholder event to drive consensus on priority patient inputs, methods, and research that more fully represent the patient perspective in comparative effectiveness research and economic evaluations of health care interventions.
The program, Designing Equitable Measures and Methods for Patient Priorities in Healthcare Value Assessment, is partially funded through a Patient-Centered Outcomes Research Institute (PCORI) Eugene Washington PCORI Engagement Award (# EAIN-21156). PCORI is an independent, nonprofit organization authorized by Congress in 2010 to fund research that will provide patients, their caregivers, and clinicians with the evidence-based information needed to make better-informed healthcare decisions.
The 3-part virtual summit series will take place in fall 2021. IVI and its partners will engage patient leaders and stakeholders across the health care landscape – including researchers, providers, and payers – to build consensus on how to define, collect, and use data that more fully represent the impacts on patients of disease and treatment options.
For more, read the full release.
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More